Corporate Presentation

Obesity Survodutide There is a significant overlap between obesity and liver disease ZEAL& ZEALAND PHARMA Obesity is associated with severe comorbidities, for which there are significant unmet medical needs Boehringer Ingelheim Pulmonology Asthma COPD Liver disease MASLD MASH Mental illness Depression Anxiety CVD Hypertension Heart failure ASCVD Stroke People who are overweight or have obesity ~75%¹ • MASLD T2DM Kidney disease Glomerulonephritis End-stage renal disease ~34%1 MASH CVD • ~15-30%2,3 ~10-15%4 Skin disease Psoriasis Hidradenitis suppurativa Cancer Colorectal cancer Breast cancer CKD ~20%5,6 Estimates of overlap of comorbidities are not available in literature; approximation in figure is based on individual prevalence estimates. Survodutide is licensed to Boehringer Ingelheim from Zealand Pharma, with Boehringer solely responsible for development and commercialization globally (subject to Zealand's co-promotion rights in the Nordic countries). Sources: 1. Quek et al. Lancet Gastroenterol Hepatol 2023;8(1):20-30; 2. Vinciguerra et al. Acta Diabetol 2013;50(3):443-449; 3. Pantalone et al. BMJ Open 2017;7(11):e017583; 4. Schienkiewitz et al. BMC Public Health 2012;12:658; 5. Arinsoy et al. J Ren Nutr 2016;26(6):373-379; 6. Yim & Yoo. Clin Exp Pediatr 2021;64(10):511-518. ASCVD-atherosclerotic cardiovascular disease; CKD=chronic kidney disease; COPD=chronic obstructive pulmonary disease; CVD-cardiovascular disease; MASLD=metabolic dysfunction-associated steatotic liver disease (formerly, NAFLD, or non-alcoholic fatty liver disease); MASH=metabolic dysfunction-associated steatohepatitis (formerly, non-alcoholic steatohepatitis, or NASH); T2DM-type 2 diabetes mellitus. 30

View entire presentation